The Impact of Vatinoxan on the Concentrations of Medetomidine, Midazolam, and Fentanyl in Central Nervous System After Subcutaneous Co‐Administration in Rats
Open Access
- 21 April 2025
- journal article
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 48 (5) , 433-438
Abstract
Our aim was to investigate whether vatinoxan, a peripherally acting alpha2‐adrenoceptor antagonist, would affect the concentrations of medetomidine, midazolam, and fentanyl in the central nervous system after subcutaneous co‐administration. Twelve healthy male Wistar rats, aged between 13 and 15 weeks, were used in this study. The animals received one of two subcutaneously administered treatments: medetomidine 0.25 mg/kg, midazolam 2 mg/kg, and fentanyl 0.01 mg/kg (MMF) or MMF with 5 mg/kg of vatinoxan (MMF‐V). 15 min later, the sedated rats were humanely euthanized with intravenous pentobarbital. Plasma and tissue, including aliquots of the cortex, thalamus, pons, and lumbar spinal cord, were harvested and analyzed for drug concentrations. The treatments were compared with Bonferroni corrected t‐tests after one‐way analysis of variance. The concentrations of medetomidine (144 ± 19.4 vs. 107 ± 13.1 ng/g [mean ± 95% confidence interval]) (p = 0.04) and fentanyl (2.3 ± 0.2 vs. 1.7 ± 0.3 ng/g) (p = 0.04) in the cortex were significantly higher in the rats administered MMF‐V. Similarly, cortex: plasma drug concentration ratios were significantly higher for medetomidine, midazolam, and fentanyl after MMF‐V (p < 0.001 for all). The results confirm that vatinoxan increases early cortical exposure to subcutaneously co‐administered medetomidine and fentanyl.Keywords
Funding Information
- Vetcare
This publication has 20 references indexed in Scilit:
- Concentrations of vatinoxan and xylazine in plasma, cerebrospinal fluid and brain tissue following intravenous administration in sheepVeterinary Anaesthesia and Analgesia, 2021
- Effects of intramuscular vatinoxan (MK-467), co-administered with medetomidine and butorphanol, on cardiopulmonary and anaesthetic effects of intravenous ketamine in dogsVeterinary Anaesthesia and Analgesia, 2020
- Concentrations of medetomidine enantiomers and vatinoxan, an α2-adrenoceptor antagonist, in plasma and central nervous tissue after intravenous coadministration in dogsVeterinary Anaesthesia and Analgesia, 2020
- Peripheral α2-adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugsVeterinary Anaesthesia and Analgesia, 2018
- Pharmacokinetics of dexmedetomidine, MK-467 and their combination following intramuscular administration in male catsVeterinary Anaesthesia and Analgesia, 2017
- The impact of MK-467 on sedation, heart rate and arterial blood pressure after intramuscular coadministration with dexmedetomidine in conscious catsVeterinary Anaesthesia and Analgesia, 2017
- Effects of constant rate infusions of dexmedetomidine or MK-467 on the minimum alveolar concentration of sevoflurane in dogsVeterinary Anaesthesia and Analgesia, 2017
- Plasma concentration and cardiovascular effects of intramuscular medetomidine combined with three doses of the peripheral alpha2-antagonist MK-467 in dogsVeterinary Anaesthesia and Analgesia, 2017
- Dexmedetomidine Produces a Hypnotic–Anesthetic Action in Rats via Activation of Central Alpha-2 AdrenoceptorsAnesthesiology, 1989
- A peripherally acting alpha-2 adrenoceptor antagonist: L-659,066.The Journal of Pharmacology and Experimental Therapeutics, 1988